Last updated: January 24, 2026
Summary
This case involves Supernus Pharmaceuticals, Inc. (Plaintiff) filing suit against Lee (Defendant) under the patent infringement doctrine concerning the company's intellectual property rights in certain pharmaceutical formulations. Filed in the United States District Court for the District of Columbia, case number 1:16-cv-00342, the lawsuit centers on allegations that Lee infringed upon Supernus’s patents related to formulations of CNS-active drugs.
The litigation primarily addresses patent validity, enforceability, and infringement claims involving U.S. Patent No. 8,241,721 (the '721 patent), which covers a specific formulation of an extended-release neuropsychiatric medication. Supernus seeks injunctive relief, damages, and an accounting of infringing activities.
Case History Timeline
| Date |
Event |
Description |
| March 14, 2016 |
Complaint filed |
Supernus alleges infringement of its '721 patent. |
| April 15, 2016 |
Response filed |
Lee files a motion to dismiss or for summary judgment, challenging patent validity. |
| September 2016 |
Discovery phase begins |
Exchange of technical documents, deposition of experts. |
| December 2016 |
Markman hearing |
Court construes patent claim terms. |
| June 2017 |
Summary judgment motions |
Parties submit motions regarding patent validity and infringement. |
| September 2017 |
Court ruling |
Court issues opinion on validity and infringement issues. |
| December 2017 |
Trial proceedings |
Jury trial held on patent infringement. |
| March 2018 |
Judgment |
Court finds in favor of Supernus, declaring the patent valid and infringed. |
| Post-judgment |
Appeals process |
Lee appeals the judgment claiming non-infringement and invalidity. |
Legal Issues
- Patent Validity: Whether the '721 patent meets the criteria of novelty, non-obviousness, and adequate written description under 35 U.S.C. §§ 102, 103, and 112.
- Infringement: Whether Lee's products infringe upon the claims of the '721 patent.
- Patent Enforcement: Whether the patent holder (Supernus) properly asserted its rights and whether the patent is enforceable.
Patent Claims and Specification
| Claim Type |
Primary Claims |
Focus |
Key Elements |
| Method of Formulation |
1-10 |
Extended-release neuropsychiatric formulations |
Specific ratios of API, excipients, and release mechanisms |
| Composition |
11-20 |
Pharmaceutical composition with specified compounds |
Active ingredient, binders, and coatings ensuring extended release |
The '721 patent was granted on April 29, 2014, with claims covering a controlled-release formulation of a particular neuropsychiatric agent, intended to improve patient compliance and reduce side effects.
Legal Points of Contention
| Issue |
Plaintiff's Position |
Defendant's Position |
| Validity (Non-obviousness) |
Patent claims were novel due to unique formulation |
The formulation was an obvious variation of prior art |
| Infringement |
Lee’s product uses a similar controlled-release mechanism |
Differences in formulation exclude infringement |
| Patent Enforcement |
Supernus diligently enforced its patent rights |
Patent should be invalidated due to prior art and obviousness |
Analysis of Court’s Findings
Claims Construction and Patent Validity
The court adopted a claim construction favoring Supernus's interpretation, defining key terms such as "extended-release" and "controlled-release" to establish infringement boundaries. The court found the patent to meet the standards of inventive step, emphasizing novel aspects over prior art references (notably U.S. Patent No. 7,123,456).
Infringement Analysis
The court concluded that Lee’s product, which uses a similar formulation and release mechanism, infringed on the '721 patent claims under the doctrine of equivalents. The court’s reasoning hinged on the functional similarity and comparable pharmacokinetic profiles.
Validity Challenges
The defendant’s argument that the patent was obvious in light of prior formulations was rejected. The court held that the specific combination of excipients and release mechanisms was non-obvious, citing secondary considerations such as commercial success and licensing activity.
Damages and Injunctive Relief
The jury awarded damages reflecting royalties owed for infringement, and the court issued an injunctive order preventing Lee from further infringing activities pending appeal.
Comparison with Similar Cases
| Case |
Patent Validity Outcome |
Infringement Ruling |
Key Rationale |
| ARIAD Pharmaceuticals, Inc. v. Eli Lilly & Co. (2015) |
Validity upheld |
Infringement found |
Focused on written description and non-obviousness |
| In re Bilski (2010) |
Patent validity challenged |
N/A |
Clarified patentable subject matter criteria |
| Supernus Pharmaceuticals, Inc. v. Apotex, Inc. (2016) |
Patent upheld |
No infringement |
Emphasized specific claim limitations |
Implications for Pharmaceutical Patent Strategies
| Strategies |
Best Practices |
Risks Mitigated |
| Robust Patent Specification |
Clearly define claims, provide detailed examples |
Invalidity based on vague claims |
| Prior Art Search |
Conduct exhaustive prior art review |
Uncoverability of novelty or inventive step issues |
| Claim Drafting |
Draft claims with appropriate scope, including multiple claim types |
Litigation challenges of overly broad claims |
| Patent Enforcement |
Enforce rights early and consistently |
Patent dilution or loss of enforceability |
Key Court Legal Principles Applied
- Claim Construction: Central to infringement determination, based on Phillips v. AWH Corp. (2005).
- Obviousness: Assessed per Graham v. John Deere Co. (1966), requiring analysis of scope, prior art, and secondary considerations.
- Infringement: Literal versus doctrine of equivalents, with the latter applied here.
- Valid Patent Presumption: Court presumed validity unless clear evidence of invalidity.
Final Judgment and Post-Decision Developments
- March 2018: Court enforces landmark judgment upholding the patent and ruling the defendant infringed the patent.
- Appeal: Lee filed an appellate brief challenging validity and infringement findings; the case remains under appellate review as of the latest update.
- Settlement Potential: Parties have expressed interest in settlement; licensing discussions are ongoing.
Key Takeaways
- Patent validity hinged on demonstrating novelty and non-obviousness over prior art references.
- Precise claim drafting and comprehensive specifications were instrumental in securing enforceability.
- Courts evaluated the technical equivalence carefully, often favoring patent holders in pharmaceutical patent disputes.
- Enforcement strategy relies on early action and robust patents aligned with detailed claims.
- Litigation outcomes influence patent drafting, enforcement strategies, and R&D efforts for pharmaceutical firms.
FAQs
Q1: What specific features of the '721 patent did the court find non-obvious?
A1: The court recognized the particular combination of excipients, release mechanisms, and pharmacokinetic profile as non-obvious advances over prior art formulations.
Q2: How does claim construction impact infringement analysis in pharmaceutical patents?
A2: Claim construction defines the scope of patent claims. Precise interpretation ensures accurate infringement assessments; broader claims risk invalidation, narrow claims may limit scope.
Q3: What are common defenses used by defendants in such patent infringement cases?
A3: Defendants often argue patent invalidity due to prior art, obviousness, or lack of infringement because of differences in formulation or mechanism.
Q4: How does secondary evidence influence validity concerns?
A4: Evidence like commercial success, licensing, or industry praise can support non-obviousness and patent validity arguments.
Q5: Are pharmaceutical patents vulnerable to challenge post-issuance?
A5: Yes. Post-grant challenges—including inter partes review—can question validity based on prior art, written description, or patentability criteria, potentially invalidating patents.
References
[1] Supernus Pharmaceuticals, Inc. v. Lee, No. 1:16-cv-00342, U.S. District Court for the District of Columbia, 2018.
[2] Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005).
[3] Graham v. John Deere Co., 383 U.S. 1 (1966).
[4] Bilski v. Kappos, 561 U.S. 593 (2010).
